Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPARHT trial of dapagliflozin for renal protection after heart transplantation
NL-OMON58986Phase 3Active, not recruiting
- Sponsor
- Oslo University Hospital
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in chronic kidney disease (CKD), sponsored by Oslo University Hospital. Started Aug 2023; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON58986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58986.